Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Back to Search
Print
Bookmark Trial

NCT02697773

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Alabama Orthopaedic Surgeons
Birmingham, Alabama, 35235, United States
See other locations
Contact
877-355-2010
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

877-355-2010

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis, Knee, Osteoarthritis, Hip
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of Osteoarthritis of the knee or hip confirmed by X-ray

- Documented history that subject tried the following medications and had insufficient pain relief or is cannot take or tolerate them: acetaminophen, NSAIDs and either tramadol or opioids

- Meet the protocol requirements for pain at screening and pain, physical function and patient global assessment of osteoarthritis at baseline

- Willing to discontinue all pain medications except study medication and rescue medication during the course of the study and use those as directed per protocol

- Women able to have children must agree to use 2 forms of contraception during the study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Body Mass Index (BMI) greater than 39


- History of diseases other than osteoarthritis in a shoulder, hip or knee (example,
rheumatoid arthritis, gout, joint infections, osteonecrosis)


- Patients with x-ray showing joint conditions such as osteonecrosis (dead bone) or
certain types of fractures


- Patients who have had significant trauma or surgery to a knee, hip or shoulder within
the previous year


- Planned surgical procedure during the study


- Patients who are largely or wholly incapacitated (example bedridden or confined to a
wheelchair, permitting little or no self-care)


- Patients who would be unwilling or unable to undergo joint replacement surgery if one
eventually became necessary


- Patients with significant conditions other than osteoarthritis that could interfere
with assessment of pain in the joints (example fibromyalgia, lupus erythematosus)


- Patients with significant heart, neurological or psychiatric diseases


- Patients who had cancer other than certain skin cancers within the past 5 years


- Patients with alcohol, analgesic (pain medications) or drug abuse within the past 2
years


- Women who are pregnant, breast-feeding or intending to become pregnant or breast-feed
during the course of the study.

Trial Details
Administration
The form in which the study drug will be delivered to the patient's body.
Subcutaneous injections
Placebo
A placebo often looks like the investigational medication, but it has no active ingredient in it.
Yes only
Trial Procedures
Physical examination
Vital signs and measurements
X-rays
Electrocardiogram (ECG)
Blood test
Keeping a diary
Questionnaire

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Osteoarthritis, Knee, Osteoarthritis, HipEfficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee NCT02697773
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Phoenix, Arizona
  4. Surprise, Arizona
  5. Tucson, Arizona
  6. Tucson, Arizona
  7. Little Rock, Arkansas
  8. Anaheim, California
  9. Covina, California
  10. Fullerton, California
  11. Irvine, California
  12. Irvine, California
  13. North Hollywood, California
  14. San Diego, California
  15. San Diego, California
  16. Upland, California
  17. Boulder, Colorado
  18. Bridgeport, Connecticut
  19. Stamford, Connecticut
  20. Fort Myers, Florida
  21. Hialeah, Florida
  22. Miami, Florida
  23. Miami, Florida
  24. Miami, Florida
  25. Orlando, Florida
  26. Ormond Beach, Florida
  27. Tamarac, Florida
  28. The Villages, Florida
  29. Atlanta, Georgia
  30. Gainesville, Georgia
  31. Honolulu, Hawaii
  32. Chicago, Illinois
  33. Chicago, Illinois
  34. Chicago, Illinois
  35. Chicago, Illinois
  36. Brownsburg, Indiana
  37. West Des Moines, Iowa
  38. Wichita, Kansas
  39. New Orleans, Louisiana
  40. North Attleboro, Massachusetts
  41. Rochester Hills, Michigan
  42. Flowood, Mississippi
  43. Las Vegas, Nevada
  44. Freehold, New Jersey
  45. Albuquerque, New Mexico
  46. Hartsdale, New York
  47. Raleigh, North Carolina
  48. Fargo, North Dakota
  49. Franklin, Ohio
  50. Tiffin, Ohio
  51. Oklahoma City, Oklahoma
  52. Oklahoma City, Oklahoma
  53. State College, Pennsylvania
  54. Greenville, South Carolina
  55. Rapid City, South Dakota
  56. Nashville, Tennessee
  57. Arlington, Texas
  58. Austin, Texas
  59. Baytown, Texas
  60. Dallas, Texas
  61. Fort Worth, Texas
  62. Houston, Texas
  63. Houston, Texas
  64. Plano, Texas
  65. Chesapeake, Virginia
  66. Danville, Virginia
  67. Richmond, Virginia
  68. Bellevue, Washington
  69. Brampton, Ontario
  70. Burlington, Ontario
  71. Guelph, Ontario
  72. Hamilton, Ontario
  73. Kitchener, Ontario
  74. London, Ontario
  75. Mississauga, Ontario
  76. Oakville, Ontario
  77. Oshawa, Ontario
  78. Sarnia, Ontario
  79. Montreal, Quebec
  80. Quebec City, Quebec
  81. Sherbrooke, Quebec
  82. Quebec,
  83. Quebec,
  84. Quebec,
  85. Quebec,
  86. Ponce,
  87. San Juan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
Official Title  ICMJE A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE
Brief Summary The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 doses of placebo. The study also evaluates the safety of the treatment regimens.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Osteoarthritis, Knee
  • Osteoarthritis, Hip
Intervention  ICMJE
  • Other: Placebo
    Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
  • Biological: Tanezumab 2.5 mg
    Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
  • Biological: Tanezumab 2.5mg/5mg
    Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
    Other Name: Titration Arm
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    placebo administered subcutaneously at day 0 and week 8
    Intervention: Other: Placebo
  • Experimental: Tanezumab 2.5 mg
    tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
    Intervention: Biological: Tanezumab 2.5 mg
  • Experimental: Tanezumab 2.5mg/5mg
    tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
    Intervention: Biological: Tanezumab 2.5mg/5mg
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 10, 2018)		698
Original Estimated Enrollment  ICMJE
 (submitted: February 26, 2016)		690
Actual Study Completion Date  ICMJE May 14, 2018
Actual Primary Completion Date December 5, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of Osteoarthritis of the knee or hip confirmed by X-ray
  • Documented history that subject tried the following medications and had insufficient pain relief or is cannot take or tolerate them: acetaminophen, NSAIDs and either tramadol or opioids
  • Meet the protocol requirements for pain at screening and pain, physical function and patient global assessment of osteoarthritis at baseline
  • Willing to discontinue all pain medications except study medication and rescue medication during the course of the study and use those as directed per protocol
  • Women able to have children must agree to use 2 forms of contraception during the study

Exclusion Criteria:

  • Body Mass Index (BMI) greater than 39
  • History of diseases other than osteoarthritis in a shoulder, hip or knee (example, rheumatoid arthritis, gout, joint infections, osteonecrosis)
  • Patients with x-ray showing joint conditions such as osteonecrosis (dead bone) or certain types of fractures
  • Patients who have had significant trauma or surgery to a knee, hip or shoulder within the previous year
  • Planned surgical procedure during the study
  • Patients who are largely or wholly incapacitated (example bedridden or confined to a wheelchair, permitting little or no self-care)
  • Patients who would be unwilling or unable to undergo joint replacement surgery if one eventually became necessary
  • Patients with significant conditions other than osteoarthritis that could interfere with assessment of pain in the joints (example fibromyalgia, lupus erythematosus)
  • Patients with significant heart, neurological or psychiatric diseases
  • Patients who had cancer other than certain skin cancers within the past 5 years
  • Patients with alcohol, analgesic (pain medications) or drug abuse within the past 2 years
  • Women who are pregnant, breast-feeding or intending to become pregnant or breast-feed during the course of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Puerto Rico,   United States
Removed Location Countries Belgium
 
Administrative Information
NCT Number  ICMJE NCT02697773
Other Study ID Numbers  ICMJE A4091056
2013-002222-23 ( EudraCT Number )
OA TITRATION STUDY ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP